Question explored with the scientific record
Does Taladafil cause glaucoma?
I cannot retrieve the evidence needed to answer this question. The records provided contain no studies on tadalafil and glaucoma, no data on intraocular pressure, and no information on the relevant patient populations. The question asks about a specific harm that the retrieval did not surface.
What the retrieval did surface is a 2003 study on tadalafil's cardiovascular effects [1], a 2005 review of PDE5 inhibitor cardiac safety [2], a 2015 pediatric pulmonary hypertension trial [3], and a 2004 drug-interaction study [4]. None of these measured intraocular pressure, examined the anterior chamber, or followed patients for glaucoma. A 2000 study on cataract surgery in microphthalmos [5] is about a different drug class entirely and a different eye condition.
The mechanism question is real: PDE5 inhibitors relax smooth muscle, and the eye's drainage pathway is smooth muscle. Tadalafil carries a label warning about non-arteritic anterior ischemic optic neuropathy (NAION), a different optic nerve condition. But whether tadalafil raises intraocular pressure enough to cause or worsen glaucoma is simply not answered by anything retrieved here. No study in this record block tested it.
My call: the evidence retrieved does not address whether tadalafil causes glaucoma. The absence is a fact about the search, not a finding about the drug. Confidence: not clear.
Sources used 5
-
Cardiovascular effects of tadalafil
This study investigates the cardiovascular effects of tadalafil, revealing that it causes minimal changes in blood pressure in healthy subjects and patients with coronary artery disease, with implications for its safe use in these populations.
DOI: 10.1016/s0002-9149(03)00074-2 -
Cardiac Safety in Clinical Trials of Phosphodiesterase 5 Inhibitors
PDE5 inhibitors (sildenafil, tadalafil, vardenafil) appear cardiovascularly safe in humans, causing only mild blood pressure reductions without clinically meaningful QT prolongation or increased major adverse cardiovascular events, though nitrates remain contraindicated.
DOI: 10.1016/j.amjcard.2005.07.010 -
Oral Tadalafil in Children with Pulmonary Arterial Hypertension
Open-label, multicenter study assessing the safety and efficacy of oral tadalafil (1 mg/kg daily) in 25 children with pulmonary arterial hypertension, showing significant reductions in mean pulmonary arterial pressure and acceptable tolerability, whether as initial therapy or af…
DOI: 10.1055/s-0034-1395510 -
INTERACTION BETWEEN THE PHOSPHODIESTERASE 5 INHIBITOR, TADALAFIL AND 2 α-BLOCKERS, DOXAZOSIN AND TAMSULOSIN IN HEALTHY NORMOTENSIVE MEN
This study investigates the hemodynamic interactions between tadalafil, a phosphodiesterase type 5 inhibitor, and the alpha-blockers doxazosin and tamsulosin in healthy normotensive men, finding that tadalafil significantly augments the hypotensive effects of doxazosin but has m…
DOI: 10.1097/01.ju.0000142687.75577.e4 -
Tadalafil improves oxygenation in a model of newborn pulmonary hypertension
This study investigates the effects of tadalafil, a phosphodiesterase-5 inhibitor, on pulmonary and systemic hemodynamics, cardiac output, and arterial oxygenation in a newborn piglet model of pulmonary hypertension, demonstrating significant improvements in these parameters fol…
DOI: 10.1097/PCC.0b013e31816c7035